Pneumococcal resistance: The treatment challenge

Annals of Pharmacotherapy

Volumn 35, Issue 4, 2001, Pages 480-488

  Amsden, Guy W ^a   Amankwa, Kwadwo ^b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

Author keywords

Fluoroquinolone; Macrolide; Pneumococci; Streptococcus pneumoniae; lactam

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; HUMAN; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROPHYLAXIS; RECEPTOR AFFINITY; REVIEW; STREPTOCOCCUS PNEUMONIAE; UPPER RESPIRATORY TRACT; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BETA-LACTAM RESISTANCE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FLUOROQUINOLONES; HUMANS; MACROLIDES; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035096577     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10080     Document Type: Review

References (59)

1. Pneumococcus and the Brooklyn connection
2. Drug-resistant Streptococcus pneumoniae: Rational antibiotic choices
3. Defining the public health impact of drug resistant Streptococcus pneumoniae: Report of a working group
4. Community-acquired pneumonia guidelines - An international comparison
5. Pneumococcal disease and the role of conjugate vaccines
6. Unusual manifestations of invasive pneumococcal infection
7. Therapy for pneumococcal infection at the millennium: Doubts and certainties
8. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America
9. New faces of an old pathogen: Emergence and spread of multidrug-resistant Streptococcus pneumoniae
10. Drug resistant Streptococcus pneumoniae: Rational antibiotic choices
11. Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic and microbiologic features
12. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective US study
13. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
14. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 and 1995: Results of a 30-center national surveillance study
15. Survey of bloodstream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program
16. Resistance pattern of Streptococcus pneumoniae in children during a four-year period in Greece
17. Resistance patterns of Streptococcus pneumoniae from children in central Italy
18. In-vitro activity of 21 β-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae
19. Austrian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae 1994-96
20. The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory-tract infections
21. Antibiotic resistance: A current perspective
22. Pneumococcal disease in Sweden: Experiences and current situation
23. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study
24. Trends in antimicrobial resistance of Streptococcus pneumoniae in children in a Turkish hospital
25. Pneumococcal infections in New Zealand
26. Pneumococcal infections in Victoria, Australia
27. In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae
28. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicentre surveillance study
29. Pneumococcal macrolide resistance - Myth or reality?
30. Molecular mechanisms of resistance to commonly used non-beta lactam drugs in Streptococcus pneumoniae
31. Incidence of erythromycin resistance in Streptococcus pyogenes: A 10-year study
32. Community-acquired pneumonia in adults: Guidelines for management. Guidelines from the Infectious Diseases Society of America
33. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin and trovafloxacin
34. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
35. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
36. Activities of fluoroquinolones against Streptococcus pneumoniae. Type II topoisomerases purified as recombinant proteins
37. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
38. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program
39. Streptococcus pneumoniae
40. Linezolid
41. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
42. Resistance to penicillin and cephalosporins and mortality, from severe pneumococcal pneumonia in Barcelona, Spain
43. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP)
44. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease
45. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - A report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group
46. Comparison of E-test to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides
47. Comparison of the plasma, urine, and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects
48. Healthy volunteer pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leukocytes and inflammatory vs. non-inflammatory skin blisters
49. Pharmacokinetics of azithromycin in rats and dogs
50. Activities of antimicrobial agents against intracellular pneumococci
51. Pharmacodynamics of levofloxacin
52. A randomized crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections
53. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
54. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
55. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
56. Strategies for the control of pneumococcal diseases
57. Pneumococcal vaccines: History, current status, and future directions